Stopping smoking: why report your prescribed medicines?

When stopping smoking, tell the healthcare professionals who manage your prescribed treatments. The NICOPATCHLIB 7 mg/24 hours transdermal patch leaflet says stopping can change the effects of other medicines, with or without this product. Using nicotine replacement therefore does not remove the need for this check.

The product information explains the role of certain substances in smoke: they stimulate enzymes involved in breaking down medicines, including CYP1A2. When smoke exposure ends, that stimulation decreases and concentrations of some medicines can rise. This mechanism is linked to hydrocarbons in smoke rather than nicotine alone.

An unchanged prescription may therefore need checking. The product information describes possible overexposure in people whose treatment was stable before stopping smoking. For some of these medicines, this change can have significant clinical consequences. The prescriber needs to assess this risk and the appropriate follow-up.

Theophylline and clozapine are two examples listed in the NICOPATCHLIB leaflet. The product information for CLOZAPINE EG LABO 100 mg, scored tablets, says abruptly stopping smoking can increase its blood concentrations and adverse effects. These examples help raise a follow-up question about treatment already prescribed.

Say whether you smoke, whether stopping is planned or has started, and whether your habits have changed recently. The CLOZAPINE EG LABO leaflet asks you to tell the doctor about smoking and warns that sudden changes can alter its effects. Show the full medicine names to make this discussion precise.

Any treatment adjustments belong to the doctor. The NICOPATCHLIB leaflet assigns necessary adjustments to them; the CLOZAPINE EG LABO leaflet says not to change the dose or stop without their advice. Do not change a prescription yourself to compensate for stopping smoking: clarify the follow-up that supports this change.